[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520661":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":24,"interventions":30,"overallOfficials":17,"centralContacts":36,"locations":46,"responsibleParty":62,"collaborators":17,"id":64,"slug":17,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":17,"enrollmentInfo":73,"targetDuration":17,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":17,"overallStatus":49,"whyStopped":17,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Assess PSMA expression in progressive metastatic TNBC patients","uptake of radiolabelled PSMA-ligand in patients with mTNBC on PET\u002FCT images.","once at baseline prior to the start of the new anti cancer treatment",[14],{"measure":15,"description":16,"timeFrame":12},"Assess the concordance between lesions visualized on PSMA PET\u002FCT and 18F-FDG PET\u002FCT images (or brain MRI in case of brain metastases).","Matching between FDG and PSMA-labelled radiotracers uptake: on PSMA PET\u002FCT and 18F-FDG PET\u002FCT images, each lesion will be identified and faced with the other images. Each imaging pair will be classified as complete match, partial match or no match between the different types of imaging",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE",[25],{"label":26,"type":27,"description":26,"interventionNames":28},"Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET\u002FCT","EXPERIMENTAL",[29],"Diagnostic Test: Ga-PSMA PET\u002FCT",[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":17},"DIAGNOSTIC_TEST","Ga-PSMA PET\u002FCT","Patient undergo Ga-PSMA PET\u002FCT prior to the start of the new drug treatment",[26],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":17,"email":41},"Géraldine Gebhart, MD","CONTACT","025413095","geraldine.gebhart@hubruxelles.be",{"name":43,"role":39,"phone":44,"phoneExt":17,"email":45},"Loubna Taraji, Ms","025413781","loubna.taraji@hubruxelles.be",[47],{"facility":48,"status":49,"city":50,"state":17,"zip":17,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Institut Jules Bordet","RECRUITING","Brussels","Belgium","BE",{"type":54,"coordinates":55},"Point",[56,57],4.34878,50.85045,{"lat":57,"lon":56},[60],{"name":61,"role":39,"phone":17,"phoneExt":17,"email":45},"Loubna Taraji Schiltz",{"type":63,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100520661",false,"NCT06059469","PSMA-PET\u002FCT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET\u002FCT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","PRISMA","Inclusion Criteria:\n\n* Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure\n* Women with ≥ 18 years-old\n* Eastern Cooperative Oncology Group Performance Status of 0 to 2\n* Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET\u002FCT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET\u002FCT.\n* Radiolabelled PSMA PET\u002FCT has to be performed before the next treatment line initiation\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Other active neoplastic disease\n* Treatment by another molecule that is the object of investigation within 30 days\n* Skin only metastatic disease\n* Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study","FEMALE","18 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET\u002FCT imaging in mTNBC lesions pre-identified on 18F-FDG PET\u002FCT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.",[81],"TNBC - Triple-Negative Breast Cancer","2025-07-15",{"date":84,"type":85},"2025-07-18","ACTUAL",{"date":87,"type":85},"2022-05-30",{"date":89,"type":75},"2025-12",{"name":5,"class":6},1]